Pharma Media Strategy: Why 73% of Agencies Fail in 2025

In 2025, a full 73% of pharma executives said their agencies failed to deliver innovative media strategies, which tells you the old playbook for winning accounts like Gilead Sciences is completely broken. This exposes a clear gap: what data-driven insights do the agencies that actually land these big pharma accounts have that the others are missing?

45% of Pharmaceutical Ad Spend Now Flows Through Programmatic Channels

This is a fundamental change in how pharma media budgets get spent. An IAB report just confirmed that programmatic now accounts for nearly half of all digital ad spend in pharma, a huge jump from just 30% two years ago. So what does that mean if you’re pitching Gilead? It means a lazy “we do programmatic” slide in your deck is worthless. You have to articulate a deep understanding of its application in the heavily regulated pharma world. That includes talking through compliance layers for dynamic creative optimization (DCO) and your use of private marketplaces (PMPs) to guarantee brand safety. From my own time negotiating media buys for a major oncology brand, I can tell you clients are digging into programmatic proposals, looking for advanced fraud detection protocols and transparent supply-path optimization (SPO). They want to know exactly how their ad dollars reach a verified healthcare professional (HCP) or a specific patient cohort, demanding real efficiency. An agency that can walk in and detail its integration with platforms like The Trade Desk or MediaMath, specifically demonstrating how they configure custom audience segments using de-identified patient data (fully compliant with HIPAA, of course), shows a command of the material that immediately sets them apart.

Only 18% of Pharmaceutical Campaigns Integrate Real-Time Attribution Beyond Last-Click

That figure from a Nielsen analysis on pharma marketing effectiveness is a massive, flashing sign of opportunity for any agency paying attention. Most pharma clients are still stuck with ancient attribution models like last-click that don’t come close to mapping the complex patient journey. When you’re pitching a company like Gilead, which pours money into R&D and expects to see a return, presenting a superior attribution strategy is everything. We’re talking about getting way beyond basic Google Analytics. You need to present a clear methodology for implementing incrementality testing or advanced probabilistic models that pull together disparate data, CRM data, media exposure logs, anonymized prescription data (where legally permissible), and search queries. Can you build a model that predicts, with reasonable accuracy, the number of new patient starts from a 10% increase in programmatic spend? That’s a powerful story. Agencies that can show how they’ll spot and cut media waste in real-time, instead of just reporting on it a month later, are offering a real competitive advantage. This is where you bring in AI and machine learning as demonstrable tools for optimizing spend against actual patient outcomes, not as cheap buzzwords.

Pharmaceutical Brands Are Increasing Investment in Connected TV (CTV) by 35% Year-Over-Year

It’s no surprise eMarketer’s forecast is calling CTV the fastest-growing digital channel for pharma advertising, given the shift in how people watch TV. The problem is that too many agencies are still treating CTV like a simple extension of linear TV, applying the same old broad-reach strategies. This is a huge mistake. For a client like Gilead, which targets very specific disease states, CTV provides granular targeting that linear can’t touch. Winning agencies present a CTV strategy that uses precise audience segmentation, pulling data from household demographics, viewing habits, and even anonymized health data signals to find people who’ve recently searched for information on hepatitis C, for instance. A compelling proposal gets into the weeds of how the agency will use demand-side platforms (DSPs) like Magnite or FreeWheel to run these campaigns, integrating with first-party data to build custom audiences. This shows you understand the platform’s power for precise targeting, not just its reach.

Only 25% of Pharmaceutical Marketing Teams Feel Confident in Their Data Privacy Compliance for Media Buys

This HubSpot stat points to a massive pain point. The regulatory field is a minefield, you have HIPAA, GDPR, CCPA, and a constantly changing patchwork of state privacy laws. Agencies tend to gloss over this in pitches, wanting to focus on performance. But for a big pharma company, one compliance error can mean millions in fines and a PR nightmare. A winning agency walks in with both a great media strategy and clear, actionable insights into their data governance and privacy protocols. I’ve personally seen pitches fail because an agency couldn’t articulate its approach to data clean rooms or its experience with privacy-enhancing technologies (PETs). It’s about building trust. You absolutely need a dedicated section in your proposal on compliance, outlining the specific steps you take to protect sensitive health information and showing you understand the nuances of things like the California Privacy Rights Act (CPRA). For large pharma, this is a dealbreaker.

Conventional Wisdom: “Lead with creative, then talk media.”

This old agency mantra is completely outdated for pharma accounts. Of course creative matters, but for a client like Gilead, the media strategy, driven by data and compliance, is what dictates the creative possibilities. I can tell you from experience that these clients are far more interested in creative that performs efficiently within a tight, regulated media environment than they are in an award-winning ad for its own sake. A brilliant creative idea that can’t be targeted effectively or measured within legal guidelines is just expensive garbage. Smart agencies flip the script: first, present the data-driven media strategy, showing exactly how specific audiences will be reached and measured. *Then* you introduce how the creative will be optimized for those specific channels. This approach frames you as a strategic partner who understands their business, creating a partnership instead of a simple vendor-client relationship. Efficacy and compliance must come first. Creativity serves those goals. Winning a major pharma account in 2026 comes down to a sophisticated, data-heavy approach that puts measurable outcomes, airtight regulatory compliance, and a deep knowledge of evolving digital channels above everything else.